- Home
- SIEB vs ATOS Comparison
SIEB vs ATOS Comparison
Compare SIEB & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- ATOS
- Stock Information
- Founded
- SIEB 1886
- ATOS 2009
- Country
- SIEB United States
- ATOS United States
- Employees
- SIEB N/A
- ATOS N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- ATOS Health Care
- Exchange
- SIEB Nasdaq
- ATOS Nasdaq
- Market Cap
- SIEB 94.9M
- ATOS 113.7M
- IPO Year
- SIEB N/A
- ATOS 2012
- Fundamental
- Price
- SIEB $3.01
- ATOS $0.83
- Analyst Decision
- SIEB
- ATOS Strong Buy
- Analyst Count
- SIEB 0
- ATOS 3
- Target Price
- SIEB N/A
- ATOS $7.00
- AVG Volume (30 Days)
- SIEB 23.7K
- ATOS 886.8K
- Earning Date
- SIEB 11-12-2024
- ATOS 11-12-2024
- Dividend Yield
- SIEB N/A
- ATOS N/A
- EPS Growth
- SIEB 61.43
- ATOS N/A
- EPS
- SIEB 0.27
- ATOS N/A
- Revenue
- SIEB $83,357,000.00
- ATOS N/A
- Revenue This Year
- SIEB N/A
- ATOS N/A
- Revenue Next Year
- SIEB N/A
- ATOS N/A
- P/E Ratio
- SIEB $11.18
- ATOS N/A
- Revenue Growth
- SIEB 27.81
- ATOS N/A
- 52 Week Low
- SIEB $1.41
- ATOS $0.77
- 52 Week High
- SIEB $3.34
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- SIEB 50.35
- ATOS 27.85
- Support Level
- SIEB $2.91
- ATOS $0.91
- Resistance Level
- SIEB $3.34
- ATOS $0.94
- Average True Range (ATR)
- SIEB 0.17
- ATOS 0.06
- MACD
- SIEB -0.03
- ATOS -0.00
- Stochastic Oscillator
- SIEB 43.10
- ATOS 1.62
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a holding company. It conducts retail discount brokerage business through its wholly-owned subsidiary. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.